Dexamethasone intravitreal implant 0.7 mg is a direct sustained-release, biodegradable dexamethasone steroid injected into the eye (vitreous) to treat adults with:
Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
Corticosteroids, block chemical pathways that lead to: Inflammation
Leakage from the retinal blood vessels
Edema of the retina.
It may help reverse some vision loss that may be caused by swelling of the macula due to retinal vein occlusion
It is the first and only injectable, biodegradable dexamethasone implant.
Possible side effects include: increased eye pressure and cataracts
Corticosteroidintravitreal implants, can cause the fluid pressure inside the eye to increase.
Some patients who receive intravitreal corticosteroid implants may develop cataracts or their existing cataracts may worsen.
It is contraindicated in the presence of any infections or diseases in the eye, or surrounding eye area, including most viral diseases of the cornea and conjunctiva, including active herpes viral infection of the eye, vaccinia, varicella, mycobacterial infections, and fungal diseases, glaucoma, torn or ruptured posterior lens capsule, that is torn or ruptured, or allergy to the implant.
Injections into the vitreous in the eye, are associated with serious eye endophthalmitis, eye inflammation, increased eye pressure, and retinal detachments.